3.0 T multiparametric prostate MRI using pelvic phased-array coil: Utility for tumor detection prior to biopsy

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 8, 2013, Pages 1430-1435

  Rosenkrantz, Andrew B ^a   Mussi, Thais C ^a   Borofsky, Michael S ^b   Scionti, Stephen S ^b   Grasso, Michael ^c   Taneja, Samir S ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c LENOX HILL HOSPITAL   (United States)

Author keywords

Biopsy; MRI; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONSENSUS; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIOLOGIST; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

BIOPSY; MRI; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TIME FACTORS;

EID: 84886278720     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.02.018     Document Type: Article

References (22)

1. Cancer facts and figures 2010 2010, American Cancer Society, American Cancer Society, Atlanta, GA.
2. Djavan B., Ravery V., Zlotta A., et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: When should we stop?. J Urol 2001, 166:1679-1683.
3. Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
4. Lujan M., Paez A., Santonja C., et al. Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions. Prostate Cancer Prostatic Dis 2004, 7:238-242.
5. Andriole G.L., Catalona W.J. Using PSA to screen for prostate cancer. The Washington University experience. Urol Clin North Am 1993, 20:647-651.
6. Langer D.L., van der Kwast T.H., Evans A.J., et al. Prostate cancer detection with multi-parametric MRI: Logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging 2009, 30:327-334.
7. Turkbey B., Pinto P.A., Mani H., et al. Prostate cancer: Value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010, 255:89-99.
8. Haffner J., Lemaitre L., Puech P., et al. Role of magnetic resonance imaging before initial biopsy: Comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011, 108:E171-E1718.
9. Tareen B., Godoy G., Sankin A., et al. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?. BJU Int 2009, 104:195-199.
10. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics 1955, 11:375-386.
11. Loch T., Eppelmann U., Lehmann J., et al. Transrectal ultrasound guided biopsy of the prostate: Random sextant versus biopsies of sono-morphologically suspicious lesions. World J Urol 2004, 22:357-360.
12. Lawrentschuk N., Haider M.A., Daljeet N., et al. Prostatic evasive anterior tumours: The role of magnetic resonance imaging. BJU Int 2010, 105:1231-1236.
13. Wefer A.E., Hricak H., Vigneron D.B., et al. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging, and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000, 164:400-404.
14. Roehl K.A., Antenor J.A., Catalona W.J. Serial biopsy results in prostate cancer screening study. J Urol 2002, 167:2435-2439.
15. Crawford E.D., Wilson S.S., Torkko K.C., et al. Clinical staging of prostate cancer: A computer-simulated study of transperineal prostate biopsy. BJU Int 2005, 96:999-1004.
16. Langer D.L., van der Kwast T.H., Evans A.J., et al. Intermixed normal tissue within prostate cancer: Effect on MR imaging measurements of apparent diffusion coefficient and T2-sparse versus dense cancers. Radiology 2008, 249:900-908.
17. Ahmed H.U. The index lesion and the origin of prostate cancer. N Engl J Med 2009, 361:1704-1706.
18. Tanimoto A., Nakashima J., Kohno H., et al. Prostate cancer screening: The clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging. J Magn Reson Imaging 2007, 25:146-152.
19. Kitajima K., Kaji Y., Fukabori Y., et al. Prostate cancer detection with 3 T MRI: Comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging 2010, 31:625-631.
20. Hambrock T., Fütterer J.J., Huisman H.J., et al. Thirty-two-channel coil 3T magnetic resonance-guided biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance imaging: Technique and feasibility. Invest Radiol 2008, 43:686-694.
21. White S., Hricak H., Forstner R., et al. Prostate cancer: Effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995, 195:385-390.
22. Kaji Y., Kurhanewicz J., Hricak H., et al. Localizing prostate cancer in the presence of post-biopsy changes on MR images: Role of proton MR spectroscopic imaging. Radiology 1998, 206:785-790.